InnoCare Announces Approval of Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment-Naive AML in China

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) ...
Medical Xpress

Magrolimab plus azacitidine results in promising activity in higher-risk MDS patients

Myelodysplastic syndromes (MDS) are a diverse group of bone marrow disorders in which immature stem cells do not mature to become red blood cells, white blood cells or platelets. Patients with ...
Hosted on MSN

Study shows chemo drug azacitidine damages RNA in stressed cells

The chemotherapy drug azacitidine, a frontline treatment for blood cancers such as myelodysplastic syndromes and acute myeloid leukemia, kills cancer cells partly by damaging their RNA rather than ...
Nature

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

Herein, we report the results of an open-label, single-center phase II clinical trial evaluating the efficacy of azacitidine in the setting of MRD-triggered (decrease of CD34 + donor chimerism below ...
Medical Xpress

Ivosidenib + azacitidine ups event-free survival in IDH1-mutated acute myeloid leukemia

Compared with placebo and azacitidine, the combination of ivosidenib and azacitidine prolongs event-free survival for patients with newly diagnosed IDH1-mutated acute myeloid leukemia who are ...
National Institute for Health and Care Excellence

Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts

The appraisal committee considered evidence submitted by Celgene and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...
Cure Today

Azacitidine Plus Venclexta Superior to Chemo in Acute AML

Azacitidine/Venclexta improved EFS and quality of life compared to induction chemotherapy in fit AML patients, with a 39% risk reduction in disease progression or death. The PARADIGM trial showed a ...
Medindia

Side effect(s) of Azacitidine

Review the side-effects of Azacitidine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
Nature

A pilot pharmacokinetic study of oral azacitidine

Azacitidine is a pyrimidine nucleoside analog of cytidine with hypomethylating and antileukemia activity. Azacitidine has been shown to have survival benefits in patients with high-risk ...
The New England Journal of Medicine

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase ...
Medscape

Oral Azacitidine: First Maintenance Therapy

ORLANDO, Florida — For the first time, there is a maintenance therapy for patients with acute myeloid leukemia (AML) in remission that can improve overall survival — a new oral formulation of an old ...